Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Co-Diagnostics Inc
NASDAQ CODX
Data sourced from
and
and
Co-Diagnostics Inc Operating Income Per Share for the quarter ending March 31, 2024: -0.35
Co-Diagnostics Inc Operating Income Per Share is -0.35 for the quarter ending March 31, 2024, a -4.00% change year over year. Operating income per share represents the amount of operating income generated by a company per outstanding share. It is calculated by dividing the operating income by the weighted average number of basic shares outstanding. This metric provides insights into the company's profitability from its core operations on a per-share basis. It is useful for evaluating the company's operational performance and comparing it with other companies on a per-share basis.
-
Co-Diagnostics Inc Operating Income Per Share for the quarter ending March 31, 2023 was -0.34, a -279.19% change year over year.
-
Co-Diagnostics Inc Operating Income Per Share for the quarter ending March 31, 2022 was 0.19, a -45.32% change year over year.
-
Co-Diagnostics Inc Operating Income Per Share for the quarter ending March 31, 2021 was 0.34, a 826.55% change year over year.
-
Co-Diagnostics Inc Operating Income Per Share for the quarter ending March 31, 2020 was -0.05, a 58.22% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: CODX
| CEO | Mr. Dwight H. Egan |
| IPO Date | July 12, 2017 |
| Location | United States |
| Headquarters | 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109 |
| Employees | 155 |
| Sector | Healthcare |
| Industry | Medical devices |
Description
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Key trends
Similar companies
Clearpoint Neuro Inc
NA
NA
SurModics Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email